Results 331 to 340 of about 98,296 (378)
Some of the next articles are maybe not open access.
Bisphosphonates for Osteoporosis [PDF]
New England Journal of Medicine, 2010 A 67-year-old woman is referred by her primary care physician for treatment of osteoporosis and progressive bone loss. Oral bisphosphonate therapy is recommended. Bisphosphonates suppress bone resorption by interfering with osteoclast activity. Several of these agents have been shown to prevent fractures and increase bone mineral density in patients ...
openaire +2 more sources
Bone, 2020
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
Jacqueline R, Center +2 more
openaire +2 more sources
Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
Jacqueline R, Center +2 more
openaire +2 more sources
Bisphosphonates and Osteoporosis
New England Journal of Medicine, 2002Osteoporosis affects millions of postmenopausal women in the United States alone. For white women who reach 50 years of age, the lifetime risk of vertebral fracture is about one in three, and that for hip fracture is one in six. One tenth to one fifth of the women who have a hip fracture die within a year after it occurs, and one quarter must move ...
openaire +6 more sources
2008
Bisphosphonates are potent inhibitors of osteoclast mediated bone resorption. These compounds are stable analogues of the inorganic pyrophosphate (PPi), which is an endogenous regulator of bone mineralization. Characteristics Bisphosphonates were developed in the nineteenth century for industrial use, in particular as “water softeners.” The first ...
openaire +3 more sources
Bisphosphonates are potent inhibitors of osteoclast mediated bone resorption. These compounds are stable analogues of the inorganic pyrophosphate (PPi), which is an endogenous regulator of bone mineralization. Characteristics Bisphosphonates were developed in the nineteenth century for industrial use, in particular as “water softeners.” The first ...
openaire +3 more sources
Bone, 2011
Bone metastases result in considerable morbidity, often affecting quality of life and independence over years, and may place complex demands on health care resources. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma and solid tumours affecting bone by 30-50%.
Robert E. Coleman, Eugene V. McCloskey
openaire +2 more sources
Bone metastases result in considerable morbidity, often affecting quality of life and independence over years, and may place complex demands on health care resources. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma and solid tumours affecting bone by 30-50%.
Robert E. Coleman, Eugene V. McCloskey
openaire +2 more sources
Bisphosphonates and atherosclerosis
General Pharmacology: The Vascular System, 2000Bisphosphonates are used for the treatment of bone resorption, hypercalcemia, osteoporosis and Paget's disease. Etidronate, pamidronate and clodronate also inhibit the development of experimental atherosclerosis without altering serum lipid profile. Bisphosphonates inhibit the arterial calcification, lipid accumulation and fibrosis.
openaire +3 more sources
Rheumatic Disease Clinics of North America, 2012
Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral fractures and osteonecrosis of the jaw have emerged with long-term use, raising questions regarding their ...
Catalina Orozco, Naim M. Maalouf
openaire +3 more sources
Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral fractures and osteonecrosis of the jaw have emerged with long-term use, raising questions regarding their ...
Catalina Orozco, Naim M. Maalouf
openaire +3 more sources
The kidney and bisphosphonates
Bone, 2011Bisphosphonates are eliminated from the human body by the kidney. Renal clearance is both by glomerular filtration and proximal tubular secretion. Bisphosphonates given rapidly in high doses in animal models have induced a variety of adverse renal effects, from glomerular sclerosis to acute tubular necrosis.
openaire +2 more sources
The American Journal of the Medical Sciences, 1997
The bisphosphonates are long-lived synthetic analogs of pyrophosphate, a natural, short-lived inhibitor of bone. Oral doses share similar qualities (ie, they inhibit bone resorption, poor absorption, and potential gastrointestinal irritants), but each one has a unique spectrum of potency and a probable mechanism of action.
openaire +2 more sources
The bisphosphonates are long-lived synthetic analogs of pyrophosphate, a natural, short-lived inhibitor of bone. Oral doses share similar qualities (ie, they inhibit bone resorption, poor absorption, and potential gastrointestinal irritants), but each one has a unique spectrum of potency and a probable mechanism of action.
openaire +2 more sources